ADAKVEO (crizanlizumab): revocation of EU marketing authorisation due to lack of therapeutic efficacy
This direct healthcare professional communication (DHPC) contains important information for healthcare professionals prescribing, dispensing or administering the medicine(s). It also includes a communication plan with details of intended recipients and the dissemination date.
|Therapeutic area (MeSH)||
Anemia, Sickle Cell
|Human ATC code||